The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 123:97-100, July 1966
doi: 10.1176/appi.ajp.123.1.97
© 1966 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by HAGOPIAN, V.
* Articles by BUSIEK, R. D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by HAGOPIAN, V.
* Articles by BUSIEK, R. D.

Five Cases of Pigmentary Retinopathy Associated with Thioridazine Administration

VARANT HAGOPIAN M.D.1, DOUGLAS B. STRATTON M.D.2, , and ROBERT D. BUSIEK M.D.3

1 Consultant in Ophthalmology, Boston State Hospital
2 Senior Physician in Psychiatry, Boston State Hospital
3 Senior Physician in Medicine, Boston State Hospital

Out of a population of about 2,200 patients at Boston State Hospital in September and October of 1963, 164 patients were being treated with thioridazine. As a result of ophthalmological examination, five cases of pigmentary retinopathy were discovered in a group of eight patients who were receiving dosages of more than 1800 mg. of thioridazine and no changes were observed in those patients who received less.

The five patients all presented marked chronic mental disturbances such as one is unlikely to encounter in the community. Possibly because of their confusion and disorientation, they were unable to report any subjective symptoms which they may have been experiencing, such as brownished coloration of vision and diminution of night vision. The five patients who exhibited retinal changes had been treated with thioridazine for 15 days, one month, six months, six months, and ten months respectively. All five patients had received large doses of other medications prior to the administration of thioridazine, and the possibility of cumulative or additive effects has not been ruled out.




This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
A. H. Glassman and J. T. Bigger Jr.
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Am J Psychiatry, November 1, 2001; 158(11): 1774 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
L. ANDERTON and P. BISHOP
Acute Visual Loss After Thioridazine Overdose
Am J Psychiatry, May 1, 2001; 158(5): 818 - 818.
[Full Text]


Home page
Arch OphthalmolHome page
G. K. Shah, D. B. Auerbach, J. J. Augsburger, and P. J. Savino
Acute Thioridazine Retinopathy
Arch Ophthalmol, June 1, 1998; 116(6): 826 - 827.
[Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1966 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org